Advertisement

Sopan Pharmaceuticals Limited (SOPL)

Manufacturing · Rs. 735.00 0.10 (+0.01%) as of Sep 24, 2026

Price — last 6 months

Full chart →
Open
727.00
High / Low
745.00 / 727.00
Prev. close
734.90
Volume
23,133
52-week high
—
52-week low
—
Market cap
—
Shares outstanding
—

MASTER score

Mechanical 0–100 technical ranking. Methodology →

Promoter holding—
Public holding—

Stock performance

1-week change
-2.52%
1-month change
-1.74%
3-month change
-20.71%
6-month change
—
YTD change
—
1-year change
—
1-month high
793.00
1-month low
705.00
From 52-week high
—
From 52-week low
—
180-day avg price
785.38
360-day avg price
785.38
Avg volume (1w)
23,313
Avg volume (1m)
23,223
Avg volume (6m)
45,562
Avg volume (12m)
45,562
Daily volatility (1m)
1.77%
Beta vs NEPSE (1y)
2.00

Valuation

EPS (annualized)
—
EPS (TTM)
—
P/E
—
P/B
—
Book value / share
—
ROE
—
ROA
—
Net profit margin
—
Graham number
—
Dividend yield
—
Dividend
—

P/E and P/B use the latest close over per-share values from the company's most recent filed statement. Full dividend history →

Key indicators vs Manufacturing

EPS (Rs.)
N/A
min -6.29avg 452.86max 1,712.27
—
P/E
N/A
min 22.03avg 34.83max 50.04
—
P/B
N/A
min 2.17avg 5.18max 9.28
—
Networth / Share (Rs.)
N/A
min 98.04avg 1,518.08max 5,537.13
—
ROE (%)
N/A
min 0.00avg 10.89max 30.92
—

Technical indicators

RSI (14)43.32Neutral
MACD-10.03Bullish
EMA 5742.60Bearish
EMA 20751.72Bearish
EMA 180——
SMA 50784.65Bearish
SMA 200——
Pivot levels (classic)
S3
708.33
S2
717.67
S1
726.33
PP
735.67
R1
744.33
R2
753.67
R3
762.33

Key financials — last 8 quarters

amounts in Rs · per-share in Rs

No filed statements found.

More Manufacturing stocks

SOPL — frequently asked questions

What is Sopan Pharmaceuticals Limited's share price?

Rs. 735.00 as of Sep 24, 2026, the latest NEPSE trading session (+0.01% on the day).

What dividend did SOPL pay?

No dividend on record for the most recent fiscal year in our data.

Prices from the latest NEPSE session; fundamentals from the company's published quarterly statements. Research reference only — not investment advice.